AlphaMeld
About

AI augments scientific judgment — it doesn't replace it.

AlphaMeld is built on a simple bet: the biggest leverage in drug discovery isn't more data — it's better reasoning over the data we already have. We augment your scientists; we don't replace them.

By design

Modality-agnostic.

Whether the right asset is a small molecule, antibody, peptide, ADC, or gene therapy, AlphaMeld reasons over the same biological substrate. The right therapeutic format for each program emerges from the data — not the toolkit a partner walked in with.

Small molecules

Hit-ID, lead optimization, IP runway

Biologics

Antibody design and ADC payload selection

Peptides

Targeted formats and stability engineering

Gene & cell

Disease-mechanism-aligned target nomination

Capabilities

Eight curated agents. One orchestration layer. Each runs as a FastAPI workflow with a deterministic interface.

C.01

Knowledge graph reasoning

Multi-hop traversal across targets, diseases, drugs, endpoints, and pathways.

C.02

Target identification

Genetic, druggability, IP, and safety priors triangulated into ranked candidate lists.

C.03

Indication discovery

From a single target, surface and prioritize additional indications.

C.04

Hypothesis validation

Stress-test hypotheses against KG and literature; produce a diligence dossier.

C.05

Trial design

Endpoint selection, phase-transition prediction, and competitor-aware positioning.

C.06

TPP audit

Compare defined Target Product Profiles against actual readouts; surface drift.

C.07

Safety assessment

On- and off-target liabilities, population signals, and competitor safety benchmarks.

C.08

Reports synthesis

Templated, diligence-grade reports with full provenance and source linking.

Mission

Who We Are

We are a global leader in leveraging AI, machine learning, and generative AI to revolutionize drug discovery and development. Guided by our mission to identify and accelerate transformative therapies for diseases with unmet medical needs, we harness the power of our cutting-edge AlphaMeld® platform to extract insights from vast and diverse data sets. This innovative approach drives the creation of groundbreaking drug programs and fosters successful collaborations with industry leaders. As trailblazers in AI-driven drug discovery, we continue to catalyze innovation and redefine possibilities in healthcare.

Culture

Culture and Commitment

At AlphaMeld® Corporation, we embrace diversity and combine technology with human expertise to drive healthcare innovation. Our mission is to improve patients' lives by addressing enduring healthcare challenges. We foster a collaborative, team-oriented environment built on trust, motivation, and shared goals, nurturing future leaders who understand their impact on others. Together, we create a vibrant workplace centered on diversity, learning, and innovation.

Get started

Ready to compress your discovery timelines?

See AlphaMeld run a live target-discovery workflow on your therapy area in 30 minutes.